Abstract
Objective
To assess retention, tolerability, and safety, efficacy and effects on quality of life (QoL) of eslicarbazepine acetate (ESL) add-on treatment over 6 months in a real-world adult population with partial-onset seizures.
Methods
This non-interventional, multicenter, prospective study was performed in eight European countries. Adult patients (n = 247) for whom the physician had decided to initiate ESL as add-on to an existing antiepileptic drug (AED) monotherapy were invited to participate. The study comprised three visits: baseline, and after 3 and 6 months. Data on ESL retention, efficacy, tolerability, safety, and QoL were collected.
Results
After 6 months, the retention rate of ESL was 82.2%, and 81.8% of patients reported a reduction of seizure frequency of at least 50%; 39.2% of patients reported seizure freedom at this time. The mean QOLIE-10 score improved from 2.9 (SD ± 0.8) at baseline to 2.1 (SD ± 0.8) after 6 months. 109 adverse events (AEs) were reported in 57 patients (26.0%); the majority were rated as related to ESL by the investigator and led to a discontinuation of ESL in 25 patients (11.4%). Eight patients (3.7%) suffered at least one serious AE. The most frequently reported AEs were dizziness, headache, convulsion, and fatigue.
Conclusions
This study shows that ESL was well tolerated and efficacious as add-on therapy to one baseline AED. The use of ESL in patients less refractory than those included in previous clinical trials led to higher responder and seizure freedom rates. No new safety issues were observed.
Discussion
Eslicarbazepine acetate (ESL), a once-daily anticonvulsant approved for adjunctive therapy of adults with POS has shown a favorable pharmacokinetic profile [6] and good efficacy and tolerability in controlled clinical settings [7-9, 12]. The population evaluated in this non-interventional trial showed a relatively low baseline seizure frequency (median of nine seizures in 3 months, Table 1), most likely attributable to the design of the study as early add-on study, in which only patients with monotherapy at baseline were to be included, and with differences in capturing seizure data (more frequent visits in interventional clinical trials) being another possible source of variation. Together with the possibility for an individualized dosing of ESL and adaptations of adjunct AED regimen, these aspects represent the major differences between this real-life observational study, and the pivotal clinical trials with ESL, where much higher baseline seizure frequencies were observed [7-9, 12].
The most frequent ESL target dose was 800 mg/day. Only a minority of patients required dose adaptations after titration. If required, for the vast majority of these patients, one post-titration dose change was sufficient to achieve satisfactory results. These findings suggest that ESL add-on treatment is easy to handle.
For the majority of patients, no changes of adjunct AED medications, or their dosage, were necessary under ESL add-on therapy, thus suggesting good efficacy and tolerability of the add-on treatment and indicative of a clinically unproblematic interaction profile [6]. Retention rate has been recommended as useful outcome measure for clinical trials with AEDs, as it comprises clinical drug effectiveness (efficacy and tolerability aspects) and patient choice [13]. Accordingly, the high proportion of patients who retained the treatment for 6 months (82.2%) is likely to reflect patients’ and physicians’ satisfaction with ESL add-on treatment, with the vast majority of patients stating their intent to continue with ESL add-on treatment beyond the present study. Correspondingly, reported efficacy was good, with almost 40% of the patients reporting at least 3 months of seizure freedom after 6 months and a responder rate at 6 months of 81.8% (Fig. 1). These figures are much higher than in previous clinical trials with ESL where responder rates between 30 and 40% [7-9, 12] were observed, likely attributable to a less severe seizure situation at baseline and potentially less refractory epilepsies in the patients included in the present study. This assumption is strengthened by observations from longer-term trials with other AEDs, which also suggest that outcome measures like retention may vary in dependency of the severity of epilepsy in the population studied [14].
The median of the QOLIE-10 score showed improvement after 3, and further after 6 months, indicating that ESL add-on treatment led to some improvement in health-related quality of life (Fig. 2). Therefore, it may be concluded that for the majority of the present patients, the addition of ESL to an existing monotherapy did not worsen, but rather stabilizes or even improves QoL. This finding in itself is important, as dissatisfaction with AED treatment and poor tolerability of AED regimens are well-known determinants of poor QoL [2, 3].
Subgroup analyses of ESL add-on treatment retention according to baseline AED medication indicate that ESL can be combined with the most frequently prescribed and currently monotherapy-approved AEDs, as retention rates were higher than 75% for all combinations: carbamazepine (100.0%), levetiracetam (85.5%), valproate (80.0%), and lamotrigine (75.9%). Correspondingly, reported efficacy (responder rate) at 6 months was also high when ESL was combined with the most frequent baseline AEDs: carbamazepine (92.9%), valproate (88.5%), levetiracetam (81.9%), and lamotrigine (69.8%). The apparent differences should be interpreted cautiously, due to the relatively small sample size in some subgroups. The findings of high retention and reported efficacy rates in the carbamazepine subgroup are noteworthy, as they appear to correspond to previous findings, where additional efficacy of ESL was observed also in combination with carbamazepine [12]. Eslicarbazepine and carbamazepine have been shown to display differential kinetics regarding the inactivation of voltage-gated sodium channels [5], which may be linked to differential clinical efficacy. More recently, both in humans and experimental models of epilepsy, it was demonstrated that eslicarbazepine may overcome a cellular resistance mechanism to carbamazepine [15].
In terms of reported efficacy, responder rate was also affected by the degree of failure of previous AED treatments: the highest responder rate at 6 months was seen in patients with one previously discontinued AED regimen (90.9%), followed by patients with two (82.2%) and those with ≥ 3 previous AED regimens (77.4%), corroborating previous findings [16]. In contrast, responder rate in the group of patients without any documentation of previously discontinued AED was lowest at 71.1%. At a first glance, this finding might seem contradictory. However, this group is most likely to be highly heterogeneous in terms of illness severity and treatment refractoriness [17] and could therefore contain a higher proportion of patients in whom early add-on AED therapy was consciously preferred over switching to an alternative monotherapy (e.g. due to knowledge of the underlying pathology or higher seizure density) [18]. Indeed, a post hoc subgroup analysis of the baseline seizure situation revealed the highest mean numbers of simple and complex partial seizures as well as total seizure number in these patients (over 3 months prior to baseline; not shown).
The overall analysis of tolerability was favorable and in line with the known tolerability profile of ESL [10]. Fifty-seven patients (26.0%) suffered from adverse events (AE, n = 109). The majority of the AE were considered adverse drug reactions, that is assessed as related to ESL treatment by the physician (84 AE in 49 patients). Of the 13 serious AE (in eight patients) (Table 2), nine were judged as related to ESL treatment by the physicians. One patient died during the study (cause of death unknown), but the physician did not see a causal relationship to ESL treatment. The most frequently reported events were dizziness (4.6%), headache (3.2%), convulsion (3.2%), and fatigue (2.7%); all other events were reported for less than six patients.
Compared to controlled clinical studies, the limitations of the present research are obvious and predetermined by the non-interventional, single-arm character of the trial, which only allows for descriptive analyses. The relatively low numbers especially for subgroups imposes the necessity for careful interpretation of the obtained results. Nonetheless, studies like the present one are of value for the treating physician as they help obtain a realistic picture of the real-life clinical practice, where patient populations are highly variable in terms of disease severity, adjunct medication, and comorbidities.
Taken together, the present study shows a high retention rate as well as promising reported efficacy of ESL add-on treatment in a real-life clinical setting. The treatment was well tolerated by the majority of patients and did not negatively affect health-related quality of life. Subgroup analyses indicate potentially differential effects of AED combination partners on ESL effectiveness. However, due to small sample size, these subgroup findings should be interpreted cautiously.